NanoViricides, Inc. (NYSE American: NNVC) announced that independent analyst Robert LeBoyer of Noble Capital Markets has initiated research coverage of the clinical-stage antiviral drug developer with an “Outperform” rating and a $6.00 price target. The report reviews the company’s lead programs, including its broad-spectrum antiviral candidate NV-387, along with longer-term development initiatives. NanoViricides noted that while it provided publicly available information and answered technical questions, the analyst independently developed all estimates, financial models and projections.
Separately, the company announced that President and Executive Chairman Anil R. Diwan participated in a “Fireside Chat” published by StockInvestor Daily’s IPO-Edge program, where he discussed NanoViricides’ antiviral technology platform, the potential of NV-387 against multiple viral diseases and variants, the company’s regulatory progress, including FDA Orphan Drug Designation and its Rare Pediatric Disease Designation filing for measles, as well as the resurgence of infectious diseases such as measles, mpox and Ebola. The full press release can be accessed at https://ibn.fm/7XBbY.
NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is a broad-spectrum antiviral drug planned for treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections and Measles. The company is currently focused on advancing NV-387 into Phase II human clinical trials. Another advanced drug candidate is NV-HHV-1 for the treatment of Shingles.
The company also develops NV-CoV-2 (API NV-387) for COVID-19, which does not encapsulate remdesivir, and NV-CoV-2-R, which encapsulates remdesivir within its polymeric micelles. NanoViricides believes that since remdesivir is already US FDA approved, NV-CoV-2-R is likely to be an approvable drug if safety is comparable. Remdesivir is developed by Gilead. The company has developed both drug candidates independently.
NanoViricides is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. Its platform technology and programs are based on the TheraCour nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms for the treatment of human viral diseases including HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex Virus, Varicella-Zoster Virus, Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses.
The company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if initial research is successful. As with any drug development, there can be no assurance that any of the company’s pharmaceutical candidates will show sufficient effectiveness and safety for human clinical development, or that successful lab results will lead to successful clinical trials or a successful pharmaceutical product. For the latest news and updates relating to NNVC, visit https://ibn.fm/NNVC.
